Breast cancer is the most common and second most deadly disease in women worldwide,
with breast cancer screening resulting in a steady decline in mortality rate. However, early …

Breast cancer is the most common and second most deadly disease in women worldwide,
with breast cancer screening resulting in a steady decline in mortality rate. However, early …

Introduction The addition of immune checkpoint inhibitors (ICIs) to frontline chemotherapy
has improved survival for patients with advanced triple-negative breast cancer (TNBC) …

Breast cancer (BC) is a significant global health challenge, representing the main cause of
morbidity and mortality for all women. Prognosis of breast cancer is variable, according to …

Therapeutic strategies for the treatment of breast cancer have historically been determined
by the presence or absence of hormone receptors and HER2 amplification and/or protein …

Immune-checkpoint inhibitors have profoundly changed the treatment landscape for many
tumor types. Despite marked improvements in disease control for highly immunogenic …

Abstract Purpose of Review To critically review the existing evidence on immune checkpoint
inhibitors (ICIs) in early-stage and metastatic breast cancer and discuss emerging strategies …

Immunotherapy continues to redefine the solid tumor treatment landscape, with inhibitors of
the PD-L1/PD-1 immune checkpoint having the most widespread impact. As the most …

The immune system plays a complex role in the recognition/prevention, early eradication as
well as progression of cancer. Recently, we have witnessed great momentum in the field of …

Immune Checkpoint Inhibitors (ICIs) have remarkably modified the way solid tumors are
managed, including breast cancer. Unfortunately, only a relatively small number of breast …